Form 4: NextCure Chief Scientific Officer Acquires Stock Options

NextCure's Chief Scientific Officer, Sol Langermann, was granted 117,375 stock options at an exercise price of $0.8048 on January 31, 2025.

Summary

• Sol Langermann, the Chief Scientific Officer of NextCure, Inc., was granted 117,375 employee stock options on January 31, 2025.
• The exercise price for these options is $0.8048 per share.
• One-fourth of the options will vest on January 31, 2026, with the remaining options vesting in 36 monthly installments starting February 28, 2026.
• The options expire on January 30, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.

Positives

• The granting of stock options to the Chief Scientific Officer aligns his interests with the company's long-term success.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

This is a standard practice for incentivizing key executives in publicly traded companies, particularly in the biotech sector.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for executives in the biotechnology industry, similar to companies like Amgen, Regeneron, and Gilead Sciences.
• The vesting schedule of one-fourth after one year and the remainder over three years is a typical vesting structure for executive stock options.
• The exercise price of $0.8048 is specific to NextCure's stock price at the time of the grant.

Stakeholder Impact

• Shareholders may view this positively as it incentivizes the Chief Scientific Officer to contribute to the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, insider trading, executive compensation, vesting, NextCure, NXTC, Sol Langermann